Cougar Biotechnology, Inc. (CGRB) Corporate Event Announcement Notice -
Cougar Biotechnology initiates enrollment in Phase I/II breast cancer study -
CGRB: Begins Enrollment for Ph I/II Trial of CB7630 in Advanced Breast Cancer -
CGRB: To Present At Lazard Capital Healthcare Conference @ 13:40 ET [delayed] -
CGRB: To Present At Rodman & Renshaw Investment Conference @ 14:50 ET [delayed] -
Cougar Biotechnology to Present at Lazard Capital Markets 5th Annual Healthcare Conference -
BRIEF-Cougar Biotechnology reports third-quarter results -
Cougar Biotechnology Reports Third Quarter 2008 Financial Results -
Cougar Biotechnology to Present at Rodman & Renshaw 10th Annual Healthcare Conference -
Cougar Biotechnology Presents Positive CB7630 Phase II Data at EORTC-NCI-AACR Symposium -
LAZARD CUTS COUGAR BIOTECHNOLOGY PRICE TARGET TO $32 FROM $40 -
CGRB: To Present At UBS Global Life Sciences Conference @ 15:30 ET [delayed] -
Cougar Biotechnology to Present at Citi Biotech Day -
Cougar Biotechnology Reports Second Quarter and First Half 2008 Financial Results -
CGRB: To Present At BMO Focus on Healthcare Conference @ 14:15 ET [delayed] -
Cougar Biotechnology to Present at BMO Capital Markets Focus on Healthcare Conference -
Prostate cancer drug advance hailed -
Cougar Biotechnology to Join Russell 3000 Index -